News
📈 Stocks
Abeona Therapeutics Reports 31% Revenue Growth as ZEVASKYN Launch Accelerates
(2 minutes ago)
Abeona Therapeutics sees strong commercial momentum for its RDEB therapy ZEVASKYN, reporting 31% revenue growth and broad market access despite ongoing administrative…